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Mechanisms of Airway Remodeling in
Asthma
Etsuko Tagaya1 and Jun Tamaoki1
ABSTRACT
Asthma is a chronic inflammatory disease characterized by reversible airflow limitation and airway hyperre-
sponsiveness. Persistent inflammation in airway tissues may lead to structural changes known as airway re-
modeling and consequently airway obstruction that is not fully reversible and progressive loss of lung function
over time.
It is generally accepted that airway remodeling is closely related to progression of airway hyperresponsiveness,
and the severity of asthma. The structural changes observed in chronic persistent asthma, which includes air-
way smooth muscle hypertrophy and hyperplasia, collagen deposition to sub-epithelial basement membrane,
hyperplasia of goblet cells, thickening of airway mucosa and an increase in vascularity, are derived from airway
inflammation. For instance, the thickened airway mucosa might be produced by cytokines and growth factors
released from inflammatory cells and airway epithelial cells, and associated with bronchial hyperreactivity and
asthma severity.
To date, many studies have identified candidate mechanisms and mediators for these observed structural
changes, which are thus potential targets in the treatment of asthma. In this review, we describe the recent
knowledge of the mechanisms and clinical implications of airway remodeling in asthma.
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INTRODUCTION
Asthmatic airway inflammation is generally believed
to cause tissue injury and subsequent structural
changes, so-called airway remodeling (Fig. 1). One of
the consequences of prolonged inflammation is thick-
ening of airway wall. Airway wall thickness has been
shown to be increased by as much as 50―300% in pa-
tients who have died of asthma and by 10―100% in
subjects with milder cases,1 and there is evidence
that airway wall thickness as measured radiologically
correlates with the disease severity and the length of
time with disease.
The narrowed airway lumens have been observed
in post mortem lung biopsy specimens from patients
who had fatal and nonfatal asthma.2 The pathological
changes in airways of patients with nonfatal asthma
are much less pronounced, with changes seen pre-
dominantly in small airways (2―4 mm in diameter).3,4
Pepe et al.5 revealed that a markedly increased mus-
cle mass in airway tissues obtained from subjects
with severe asthma compared with those with moder-
ate asthma. In addition, the smooth muscle was lo-
cated much closer to the epithelium in subjects with
severe asthma, perhaps reflecting a phenomenon of
migration of smooth muscle cells toward the epithe-
lial surface.
A variety of mediators have been described in air-
ways of asthmatics that could theoretically be rele-
vant to airway remodeling, but it is not entirely
known how various stimuli or mediators of the in-
flammatory response are linked to the processes of
airway remodeling. In this review of airway remodel-
ing in asthma, we will focus on structural changes ob-
served in airway epithelium, subepithelium, airway
smooth muscle and vasculature, and their proposed
mechanisms and clinical implications.
MECHANISMS OF AIRWAY REMODELING
EPITHELIAL DAMAGE, REPAIR AND GOBLET
CELL HYPERPLASIA
Airway epithelium plays an important role not only as
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Fig. 1 Airway remodeling in chronic asthma includes goblet cel hyperplasia, basement 
membrane  thickening  associated  subepithelial  fibrosis,  airway  smooth  muscle 
hypertrophy/hyperplasia and angionenesis.
Epithelial sloughing/denudation
Goblet cell hyperplasia
Increased MUC5AC expression
Basement membrane thickening
Subepithelial fibrosis
Airway smooth muscle hypertrophy/
hyperplasia/migration
Angiogenesis
Inflammatory cell recruitment
(eosinophils, Th2-lymphocytes)
barrier from the outer environment but also as the
regulator of metabolic and immunologic functions in
the airways. It has been reported that epithelial cells
are found in increased amounts in asthmatic sputum,
and epithelial detachment from the basement mem-
brane is frequently observed in the various models of
asthma. There are a lot of inflammatory factors pro-
duced by airway epithelial cells, and epithelial dam-
age participates in the proinflammatory processes
through cytokines, growth factors, and mediators in
asthma patients. The factors contributing to remodel-
ing directly are transforming growth factor (TGF),
platelet-derived growth factor (PDGF), epidermal
growth factor (EGF), basic fibroblast growth factor
(b-FGF), insulin-like growth factor-1 (IGF-1),
endothelin-1 (ET-1), and heparin-binding epidermal
growth factor (HB-EGF). These factors have been
well known to affect a proliferation of fibroblast and
an extracellular matrix production, among which
TGF-β produced by airway epithelium might be one
of the most important molecules in may of the proc-
esses of remodeling.
Airway mucus protects the epithelial surface from
injury and facilitates the removal of bacterial, cellular,
and particulate debris from the lung. Mucus produc-
tion is also an important feature of asthma and con-
tributes substantially to morbidity and mortality, es-
pecially in more severe disease. Goblet cells and sub-
mucosal glands secret mucus, and a high proportion
of goblet cells and an enlargement of submucosal
glands are associated with hypersecretion of mucus,
which may result in the narrowing of airway lumen
and, hence, aggravation of airway obstruction. Goblet
cell hyperplasia has been consistently demonstrated
in mild, moderate and severe asthma (Fig. 2). It is
also easily observed in the early stage of allergen
challenge in experimental asthma model in mice and
guinea pigs. Similarly, enlargement and hyperplasia
of mucus glands found in the subepithelium can fre-
quently be seen in asthma.
Goblet cells and mucus glands are the sources of
mucin glycoproteins (MUCs) and, to date, 13 MUC
genes (MUC1-4, MAU5AC, MAC5B, MUC6-9,
MUC11-13) have been identified in human airways.
Whereas the expression of several MUC genes in the
airway can be detected, MUC5AC gene expression
appears to predominate in both asthmatic and
nonasthmatic airways but is probably greater in the
asthmatic airway. Fahy et al.6 reported the increased
immunohistochemical expression of MUC5AC in
bronchial biopsies of asthmatic subjects. In this
study, the expression of MUC5AC, MUC2 and MUC4
were similarly increased in the same patients com-
pared with healthy subjects. Another study has
shown that the expression of EGF receptor (EGFR)
is increased in the airway epithelial cells of asthma
patients.7 This finding seems very important, because
EGFR activation can lead to mucin MUC5AC synthe-
sis and goblet cell production in human bronchial epi-
thelial cells in vitro and in rats in vivo. Indeed,
Takeyama and colleagues8 have shown that there is a
significant positive correlation between EGFR im-
munoreactivity and the area of MAC5AC positive
staining in the asthmatics and healthy subjects (Fig.
Airway Remodeling in Asthma
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Fig. 2 Structural changes in airways of patients died of asthma. A, thickening of 
(basement membrane (arow); B, hyperplasia of mucus-producing cels of submu-
cosal gland (arow); C, airway epithelial cels in healthy subject; D, goblet cel hy-
perplasia in asthma patient (arow).
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Fig. 3 Corelation between EGFR immunoreactivity and 
MUC5AC production in airway epithelium. EGFR immunore-
activity showed a significant positive corelation with the 
area of MUC5AC-positive staining.
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3). Furthermore, the expression of EGFR and
MAC5AC is upregulated in the epithelium of asthmat-
ics airways at both mRNA and protein levels and is
often colocalized in goblet cells. These results sug-
gest that the possible role of EGFR activation in mu-
cin synthesis in asthmatics airways.8
On the other hand, studies on murine asthma
model implicate the role of Th2 cytokines (IL-4, IL-5,
IL-9, and IL-13) in goblet cell metaplasia. IL-13 in-
creased the proportion of secretory cells, caused
overexpression of MUC5AC inn the same cells, and
consequently altered epithelial cell morphology in
primary culture of airway epithelial cells.9 Addition-
ally, Shim et al.10 reported that IL-13 induced goblet
cell metaplasia and MAC5AC mucin production in rat
airway epithelium, and suggested that these effects
may be attributed to EGFR activated by neutrophils
recruited into the airways.
The transcription factor STAT-1 is a key molecule
in interferon (IFN)-mediated signaling and plays a
critical part in the pathogenesis of viral infection.
There is evidence that STAT-1 is constitutively acti-
vated in epithelial cells from asthmatic subjects but
not in those from healthy subjects. STAT-1 levels are
correlated with intracellular adhesion molecule-1
(ICAM-1) expression, which is in turn associated
with T-lymphocyte accumulation into the tissue.11
Asthma patients have also an elevated level of STAT-6
in the airway epithelium. Other candidate molecules
associated with goblet cell hyperplasia are human
Ca2+-activated chloride channel-1 (CLCA1) and am-
phiregulin. Recent studies have demonstrated that
the expression of CLCA1 gene is upregulated in gob-
let cells in patients with allergic asthma12 and that
amphiregulin, one of the EGFs, produced by stimula-
tion of mast cell FceRI enhances the expression of
mucin mRNA in airway epithelium.13
SUBEPITHELIAL FIBROSIS
Histologically, reticular basement membrane thicken-
ing of airway epithelium is a characteristic feature of
asthma, which is not found in chronic obstructive pul-
Tagaya E et al.
334 Allergology International Vol 56, No4, 2007 www.jsaweb.jp
monary disease or chronic bronchitis.14,15 These
changes involve the subepithelial space and the thick-
ness can range from 7 to 23 μm in subjects who have
asthma, versus 4 to 5 μm in controls.3 The epithelial
basement membrane consists of two layers: shallow
layer (basal lamina) and deeper layer (lamina reticu-
laris). When thickened basement membrane of asth-
matic airway is observed with electron microscopy,
there is, rather, thickening of the area just below the
lamina rericularis, which is true basement mem-
brane. The thickening of subepithelial space corre-
sponds to the deposition of collagen I, III, V and ex-
tracellular matrix (ECM), such as fibronectine, lami-
nin and tenascin, and other abnormalities have also
been noted in noncollagenous matrix, including
elastine, proteoglycans and cartilage.16 The mecha-
nism of deposition of ECM is thought to be an imbal-
ance between its synthesis and degradation. Collagen
deposition in tissues is controlled by the balance of
the collagen-degrading matrix metalloproteases
(MMPs) and their inhibitors, the tissue inhibitors of
metalloproteases (TIMPs). In asthma, the potentially
most important members of this family are MMP-9
and TIMP-1. Overexpression of TIMP-1 causes depo-
sition of ECM and thickening of basement membrane
by inhibiting degradation of ECM. Studies on asth-
matic subjects have revealed the increased produc-
tion of both MMP-9 and TIMP-1 in sputum and bron-
choalveolar lavage fluid (BALF). The ratio of MMP-9
and TIMP-1 in asthmatics is lower than in control
subjects and correlates with the degree of airway ob-
struction.17 The main source of MMP-9 in asthmatic
airways is believed to be eosinophils.
TGF-β is a major cytokine that is synthesized by a
variety of cells, such as epithelial cells, macrophages,
eosinophils, lymphocytes and fibroblasts, and stimu-
lates the production of ECM. TGF-β1 mRNA appears
to be increased in moderate and severe asthmatics
compared with normal subjects, and the expression
of this cytokine is directly related to the degree of
subepithelial fibrosis.18,19 Many of the effects of IL-13
may be mediated by the metalloproteinases, IL-13
overexpression is mediated by TGF-β, and TGF-β ac-
tivation is MMP-9 dependent.20 It is possible, there-
fore, that MMP-9 could be a key molecule in the
proximal of IL-13-mediated signaling pathway. Smad7
is an inhibitory protein against intracellular signal
transduction of TGF-β and is thought to be a modula-
tor of TGF-β actions. Thus, the expression of Smad7
might be involved in the progress of thickening of
basement membrane.21 Tenascin is only expressed
during tissue repair and this observation solidifies re-
modeling’s link to chronic inflammation and tissue in-
jury.22
Some groups have identified both severe asthmat-
ics with no increase in subepithelial fibrosis and
nonasthmatics with increased subepithelial fibrosis.23
It is also proposed that subepithelial fibrosis could ac-
tually be a very early marker for the asthmatic pheno-
type in children,24,25 and that symptom severity, age,
or duration is not necessarily related to the degree of
basement membrane thickening.26 Therefore, subepi-
thelial fibrosis might simply represent disordered
epithelial-mesenchymal signaling rather than direct
response to inflammatory injury.27 Several papers
have demonstrated that thickness of basement mem-
brane has a negative relationship with %FEV1 and
provocative dose of methacholine, and other reports
have shown that the magnitude of collagen deposi-
tion is correlated with the severity of asthma and
cough variant asthma.
Myofibroblasts are specialized cells with features
of both fibroblasts and myocytes. Structurally, myofi-
broblasts display a phenotype intermediate between
fibroblasts and smooth muscle cells, express α-
smooth muscle actin, and have the ability to secrete
ECM proteins. In addition, these cells secrete
chemokines that can prolong eosinophil survival. Al-
though myofibroblasts are found predominantly in
the lamina reticularis, the origin of these cells re-
mains uncertain. Recently, Schmidt et al.28 described
that CD34+ cells expressing procollagen I and α-
smooth muscle actin were increased in the bronchial
mucosa after allergen challenge in patients with
asthma, and Batra et al.29 reported that the Th2 cy-
tokine IL-4, as well as TGF-β, stimulated fibroblasts to
express α-smooth muscle actin.
AIRWAY SMOOTH MUSCLE
An increase in airway smooth muscle mass is the
most prominent feature of airway remodeling in
asthma. Smooth muscle proliferation consists of hy-
pertrophy (an increase in size of airway smooth mus-
cle) and hyperplasia (an increase in the number of
airway smooth muscle). Ebina and colleagues30 ana-
lyzed the distribution of smooth muscle hypertrophy
in serial sections of autopsied airway specimen from
asthmatic patients by 3-D morphometric technique.
They demonstrated two types of airway smooth mus-
cle remodeling in asthmatics: hyperplasia of smooth
muscle was found only in the central airways and, in
contrast, hypertrophy involved the whole airway tree,
including bronchioles. However, the mechanism for
this difference is unknown.
The increase in smooth muscle mass is dispropor-
tionate to the increase in total airway wall thickness.
Recent studies suggest that airway smooth muscle
cells might modulate airway remodeling by secreting
cytokines, growth factors, or matrix proteins and by
expressing cell adhesion molecules and other poten-
tial costimulatory molecules. Major factors for airway
smooth muscle proliferation are shown in Table 1.
MYOCYTE HYPERPLASIA
There are numerous reviews of the mechanisms
regulating airway smooth muscle proliferation.31 In
Airway Remodeling in Asthma
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Table 1 Major factors for airway smooth muscle proliferation
InhibitoryStimulatory
PGE2Inflammatory mediatorsGrowth factors, Cytokines
HeparinHistamineEGF
β2-AgonistSerotoninPDGF
Nitric oxideEndothelin-1IGF-1, 2
CorticosteroidLTD4bFGF
Substance PIL-1β
α-ThrombinIL-6
Thromboxane A2TNF-α
TGF-β
Enzymes
Tryptase
β-Hexosaminidase
Lysosomal hydrolases
asthmatic airways, hyperplasia of airway smooth mus-
cle is an important mechanism leading to the in-
creased smooth muscle mass, and it is thought that
smooth muscle hyperplasia depends on the stimula-
tion of mitosis and the suppression of apoptosis. The
overview of the mechanisms of airway smooth mus-
cle proliferation is shown in Figure 4.32 There may be
at least three major signal transduction pathways as-
sociated with airway smooth muscle proliferation, i.e.,
the effects of mitogens are mediated through differ-
ent receptor systems: 1) receptor tyrosine kinase
(RTK), which is stimulated by PDGF, EGF, bFGF
and IGF, 2) G protein-coupled receptor (GPCR),
which is stimulated by thromboxane A2, histamine,
ET-1 and LTD4, and 3) cytokine receptor which is
stimulated by IL-6 and TNF-α.
Phosphatidylinositol 3-kinase (PI3K) and extracel-
lular signal-regulated kinase (ERK) activation ap-
pears to be the dominant signal transduction path-
ways for RTK-, GPCR-, or cytokine receptor-stimu-
lated growth of airway smooth muscle cells. In the
downstream of these three receptors, activation of
RTK or cytokine receptor induces p21ras activation
and stimulates two parallel signaling pathways, ERK
or PI3K pathway. Phosphorylation of ERK or PI3K
lead to activation of transcription factors such as c-
Jun, c-Fos and c-Myc in the nucleus and this may oc-
cur via activation of p90 ribosomal S6 kinase. ERK
phosphorylates nuclear protein such as clyclin D1 to
induce DNA synthesis and cell proliferation. D-type
cyclins (cycline D1, D2, and D3) are key regulators of
G1 progression in mammalian cells, and cyclin D1
has been the most extensively studied. PI3K phos-
phorylates membrane phosphoinositides, which func-
tion as a second messenger and activate downstream
effect of the molecules regulating cell-cycle protein
expression and thus modulate cell-cycle traversal.33
Activation of PI3K is critical for airway smooth mus-
cle cell-cycle progression,34,35 although other signal-
ing events are also necessary to promote maximal
growth responses. Stimulation of GPCR induces deg-
radation of PIP3 into diacylglycerol and inositol
triphospate, where the former activates protein
kinase C, and the latter induces the release of stored
Ca2+ from endoplasmic reticulum.
Additionally, STAT3 has been shown to play an im-
portant role in the PDGF-induced proliferation of hu-
man airway smooth muscle cells. Activation of JAK2
and STAT3 by PDGF appears to be redox dependent
and affects the proliferative responses to mitogen in-
dependent of ERK activation.36
MYOCYTE HYPERTROPHY
Airway smooth muscle hypertrophy is indicated by
an increase in size of ASM cells. Some mediators,
such as IL-1β, IL-6, TGF-β, angiotensin II and cardiot-
ropin I, induce cellular hypertrophy in vitro, although
the mechanisms remain unclear. Morphologic stud-
ies confirm the presence of airway smooth muscle
cell hypertrophy in some, but not all, asthmatic pa-
tients.30 Increased cell size appears to negatively cor-
relate with postbronchodilator FEV1 and distingui-
shes between severe persistent asthma and milder
disease.37
In contrast, Woodruff et al.38 obtained bronchial bi-
opsy specimens from patients with mild to moderate
asthma. They found no evidence of airway smooth
muscle hypertrophy, although they did confirm the
presence of hyperplasia. It is difficult to evaluate air-
way smooth muscle cell size by 3-D morphometry,
and further studies are required in this particular
area of smooth muscle cell biology.
SMOOTH MUSCLE MIGRATION
Migration of airway smooth muscle cells also likely
promotes airway remodeling in chronic asthma. Muk-
hina and colleagues39 reported that human airway
smooth muscle cells in culture are capable of migrat-
Tagaya E et al.
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Fig. 4 Schematic diagram of mitogenic signaling pathway in human airway smooth muscle 
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ing, particularly in response to urokinase plasmino-
gen activator. Afterwards, it was proved that PDGF,
TGF-β, bFGF and IL-1β increased chemotaxis of air-
way smooth muscle cells. Recent study has demon-
strates that only PDGF, but not EGF or thrombin, in-
duces migration in airway smooth muscle cells.40
INFLAMMATORY CELL INFILTRATION
Airway smooth muscle cells release various cytoki-
nes, chemokines, and growth factors through interac-
tion with inflammatory cells, thereby contributing to
modulation of airway inflammation and remodeling.
These cells have been shown to secrete RANTES,
eotaxin, IL-8, monocyte chemotactic protein (MCP)-
1, MCP-2, MCP-3, TARC (thymus and activation-
regulated chemokine), and GM-CSF in response to
TNF-α and IL-1β, and might play a role in promoting
both the recruitment and survival of eosinophils
through secretion of GM-CSF and IL-5.41,42 Airway
smooth muscle cells also express ICAM-1 and
VCAM-1, which are inducible by inflammatory media-
tors, and produce ECM proteins that promote airway
remodelling.
Mast cells also play an important role in airway re-
modeling. Mast cell degranulation and activation by
allergen-mediated cross-linking of IgE result in the
release of a variety of mediators capable of remodel-
ing airway smooth muscle cells, including tryptase,
cysteinyl LTs, and prostaglandin D2. Upon degranula-
tion, tryptase stimulates proliferation of fibroblasts
and myocytes, as well as type I collagen production.43
Activation of mast cell has long been recognized in
asthmatic airways44,45 and the number of mast cells is
increased within the smooth muscle layer.46 In addi-
tion, there is evidence that an increased number of
tryptase-positive mast cells are present in airway
smooth muscle bundles of asthmatic subjects.47
Recently, tryptase has been suggested to be an im-
portant mediator related to airway remodeling. In our
previous study, we measured serum levels of mast
cell-derived tryptase in healthy subjects and patients
with steroid-naïve mild to moderate asthma, using
B12 monoclonal antibody-based immunofluoroassay
that detects both monomers and tetramars of α- and
β tryptases. As a result, the tryptase levels were sig-
nificantly higher in asthmatics than healthy controls,
even at asymptomatic periods, and the levels were
further increased during asthma attack. There was a
negative correlation between serum tryptase levels
and FEV1 determined after treatment with β2-agonist
(Fig. 5, unpublished data).
Tryptase possess various biological actions, such
as proliferation of airway epithelial cells and fibro-
blasts,48 IL-8 production, and expression of ICAM-1.49
Other studies have shown airway smooth muscle in-
filtration by mast cells in patients with asthma,50 tryp-
tase could provide a potent stimulus for both DNA
synthesis and proliferation of human airway smooth
muscles by activating proteinase-activated receptor-2
(PAR-2).51
Expression of MMP-1 which acts to degrade IGF
binding protein, a growth inhibitor is increased in air-
way smooth muscle cells of asthma patients, and the
expression can be induced by various mitogens in-
cluding LTD4.52 Progelatinase A (MMP-2) is constitu-
tively released by airway smooth muscle cells but re-
mains inactive because of high levels of tissue inhibi-
tor of MMP-2 on the cell membrane.53 Airway
smooth muscle cells also express both pro-MMP-3
and active MMP-3.54 TNF-α stimulates the release of
MMP-9, which can degrade matrix and also plays a
critical role in cleaving latent TGF-β to its active
Airway Remodeling in Asthma
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Fig. 5 Serum tryptase levels in healthy control subjects and patients with 
asthma during stable disease and asthma atack. Asthma patients had a 
significantly higher tryptase level compared with control subjects (left 
panel). Corelation between serum tryptase levels and FEV1 measured af-
ter β2-agonist inhalation. There as a significant negative corelation be-
tween these variables, suggesting a possible contribution of tryptase to 
airway remodeling.
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form.55 A disintergrinase and metalloproteases
(ADAM) family is a subfamily of metalloproteinases
located on the cell surface of airway smooth muscle
cells and fibroblast, and polymorphisms in the
ADAM-33 gene have been shown to be associated
with airway hyperresponsiveness of asthma pa-
tients.56
BRONCHIAL NEOVASCULARIZATION
Angiogenesis and microvascular remodeling can be
seen in the airways of chronic severe asthma. These
changes are likely mediated by multiple factors, and
the increased vascularity may be produced by a num-
ber of proangiogenic molecules, especially vascular
endothelial growth factor (VEGF). VEGF is localized
to airway epithelial cells, mononuclear cells, and T
lymphocytes. Previous clinical studies suggest an im-
portant role of VEGF as a mediator of airway remod-
eling and increased vascular permeability in asthma.
Subsequently, VEGF has been appreciated to be a
multifunctional angiogenic regulator that stimulates
epithelial cell proliferation, blood vessel formation,
and endothelial cell survival.57 VEGF levels in sputum
and BALF are increased in asthmatics, and the levels
correlate directly with the disease activity. Bronchial
biopsy specimens taken from subjects with asthma
reveal an increase in airway vascularity and expres-
sion of VEGF and VEGF receptors in the bronchial
mucosa.58 In animal model of asthma, VEGF receptor
blockers inhibit both airway inflammation and airway
hyperresponsiveness.59
VEGF also causes a marked increase in inflamma-
tion by enhancing the level of Th2 cytokines, espe-
cially IL-13 and, vice versa, IL-13 causes an increase
in VEGF production. As expected from the IL-13-
overexpressing mice, VEGF levels are markedly in-
creased in BAL Fluids after allergen challenge. When
a VEGF receptor antagonist was used in vivo, there
was a dramatic decrease in airway hyperresponsive-
ness, which was accompanied by a decrease in IL-13
and IL-4 production. Interestingly, viral infection can
also lead to increased VEGF60 and it has been
thought that viral infection early in life predisposes
the onset of asthma.61 Thus, it is possible that VEGF
could play a role in the development of asthma. On
the other hand, endostatin is proposed to be the most
important inhibitory factor of neovascularisation. Pro-
liferation of vascular endothelial cells stimulated by
VEGF is potently inhibited by endostatin, but physi-
ologic role of this molecule in airway remodeling re-
mains to be elucidated.
ROLE OF CYTOKINES
Several cytokines, especially Th2 cytokines, have a
direct role in propagating the asthmatic inflammatory
processes IL-13 is critically important in acute models
of allergic inflammation,62 potently inducing eosino-
phil-, macrophage-, and lymphocyte-mediated inflam-
matory responses, subepithelial fibrosis, mucus hy-
persecretion, and airway hyperresponsiveness.63 The-
se effects are probably derived from STAT-6 signaling
pathway. In addition, IL-4 and IL-13 are also exert di-
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rect effects on airway epithelial cells and fibroblasts.
These cytokines enhance fibroblast eotaxin release,
which potentially explains the accumulation of
eosinophils into the lamina reticularis64,65 IL-11 has
been known to play a role in airway remodeling, but
the increased levels of IL-11 can be found only in the
airways of patients with more severe disease, but not
those with mild asthma.
CLINICAL IMPLICATIONS: THERAPY FOR AIR-
WAY REMODELING
It seems very important to prevent airway remodeling
in the chronic management of asthma, which leads to
prevent progress of the disease severity. A recent
study demonstrated that chronic β2-adrenoceptor
overexpression resulted in airway hyperresponsive-
ness in mice and appeared to modulate procontractile
signaling pathways.66 We have previously shown that
salbutamol, a selective β2-adrenoceptor agonist, en-
hances the growth of cultured human airway epithe-
lial cell lines through stimulation of mitogen-activated
protein (MAP) kinase (ERK12) cascade,67 more re-
cently, salbutamol stimulates proliferation of airway
epithelial cells and produces airway wall thickening
in vivo via MAP kinase-dependent pathway.68 In the
latter study, we have also found that the salbutamol-
induced structural changes can be prevented by the
simultaneous use of inhaled corticosteroid. Anti-
inflammatory therapy with Inhaled is a main stream
of maintenance treatment for all severities of asthma.
Regarding the effect on airway remodeling, corti-
costeroids have been shown to inhibit airway smooth
muscle cell migration in vitro, presumably through
the inhibition of mitogen-stimulated increase in cyclin
D1 protein.69 It has been well known that corticoster-
oid binding to the glucocorticoid receptor results in
activation of the transcription factor CEBPα, and a
recent study suggests that ASM cells derived from
patients with asthma lack the expression of CEBPα
and are therefore resistant to the effects of glucocorti-
coids on proliferation.70 Given the ability of VEGF to
promote both airway inflammation and remodeling,
the data mentioned above suggests a possible role of
VEGF antagonists in the treatment of severe asthma,
which is resistant to conventional anti-inflammatory
agents.
It has been widely recognized that peripheral air-
way inflammation play an important role in the patho-
genesis of asthma, and that the treatment of airway
remodeling should be focused on peripheral airways.
However a conventional inhaled corticosteroid seems
difficult to reach the peripheral airway. To solve this
problem, new types of inhaled corticosteroids, such
as hydrofluoroalkane-134A (HFA)-beclomethasone
has been developed, and several reports showed a re-
duction of α-smooth muscle actin area in the periph-
eral airways and an improvement of peripheral air-
flow limitation after treatment with HFA-flunisolide in
patients with mild to moderate asthma.71 Further-
more, LT receptor antagonists have been demon-
strated to inhibit airway smooth muscle proliferation
stimulated by EGF,72 and reduce subepithelial fibro-
sis and mucus hyper secretion.73 Therefore, LT re-
ceptor antagonists could be of value for preventing
airway remodeling in asthma.
REFERENCES
1. James AJ. Relationship between airway wall thickness and
airway hyperresponsivenss. In: Stewant AG (ed). Airway
wall remodeling in asthma. Boca Raton (FL): CRC Press,
1997;1-27.
2. Carroll N, Elliot J, Morton A et al. The structure of large
and small airways in nonfatal and fatal asthma. Am. Rev.
Respir. Dis. 1993;147:405-410.
3. Homer RJ, Elias JA. Consequences of long-term inflam-
mation: airway remodeling. Clin. Chest Med. 2000;21:331-
343.
4. Kumano K, Bosken C, Pare P, Wiggs B, Hogg J. Small
airways dimensions in asthma and in chronic obstructive
pulmonary disease. Am. Rev. Respi. Dis. 1993;148:1220-
1225.
5. Pepe C, Foley S, Shannon J et al. Differences in airway re-
modeling between subjects with severe and moderate
asthma. J. Allergy Clin. Immunol. 2005;116:544-549.
6. Fashy JV. Remodeling of the airway epithelium in asthma.
Am. J. Respir. Crit. Care Med. 2001;164:S46-51.
7. Amishima M, Munakata M, Nasuhara Y et al. Expression
of epidermal growth factor and epidermal growth factor
receptor immuno-reactivity in the asthmatic human air-
way. Am. J. Respir. Crit. Care Med. 1998;157:1907-1912.
8. Takeyama K, Fahy JV, Nadel JA. Relationship of epitder-
mal growth factors to goblet cell production in human
bronchi. Am. J. Respir. Crit. Care Med. 2001;163:511-516.
9. Laoukili J, Perret E, Willems T et al. IL-13 alters mucocili-
ary differentiation and ciliary beating of human respira-
tory epithelial cell. J. Clin. Invest. 2001;108:1817-1824.
10. Shim JJ, Dabbag AK, Ueki IF et al. IL-13 induced mucin
production by stimullationg epidermal growth factor re-
ceptors and by activationg neutrophils. Am. J. Physiol.
Lung Mol. Physiol. 2001;280:L134-L140.
11. Sampath D, Castro M, Look DC, Holtzman MJ. Constitu-
tive activation of an epithelial signal transducer and activa-
tor of transcription (STAT) oathway in asthma. J. Clin. In-
vest. 1999;103:1353-1361.
12. Hashimoto M, Morita S, Iwashita H et al. Increased ex-
pression of the human Ca2+ activated Cl− channel I
(CaCC 1) gene in the asthmatic airway. Am. J. Respir.
Crit. Care Med. 2002;165:1132-1136.
13. Okumura S, Sagara H, Fukuda T et al. Fc epsilon R I-
mediated amphiregulin production by human mast cells
increases mucin gene expression in epithelial cells. J. Al-
lergy Clin. Immunol. 2005;115:272-279.
14. Jeffery PK. Remodelind in asthma and chronic obstruc-
tive lung disease. Am. J. Respir. Crit. Care Med. 2001;
164:S28-38.
15. Vignola AM, Mirabella F, Costanzo G et al. Airway re-
modeling in asthma. Chest 2003;123:S417-422.
16. Lazaar AL, Panettieri RA Jr. Is airway remodeling clini-
cally relevant in asthma? Am. J. Med. 2003;115:642-659.
17. Kelly EA, Jarjour NN. Role of matrix metalloproteinases
in asthma. Curr. Opin. Pulm. Med. 2003;9:28-33.
18. Minshall EM, Leung DY, Martin RJ et al. Eosinophil-
Airway Remodeling in Asthma
Allergology International Vol 56, No4, 2007 www.jsaweb.jp 339
associated TGF-β1 mRNA expression and airways fibrosis
in bronchial asthma. Am. J. Respir. Cell Mol. Biol. 1997;
17:326-333.
19. Ohno I, Nitta Y, Yamauchi K, Hoshi H, Honma M, Wool-
ley K. Transforming growth factor β1 (TGF β1) gene ex-
pression by eosinophils in asthmatic airway inflammation.
Am. J. Respir. Cell Mol. Biol. 1996;15:404-409.
20. Lee CG, Homer RJ, Zhu Z et al. Interleukin-13 induces tis-
sue fibrosis by selectively stimulating and activating
transforming growth factor beta (1). J. Exp. Med. 2001;
194:809-821.
21. Nakao A, Sagara H, Setoguchi Y et al. Expression of
Smad7 in bronchial epithelial cells is inversely correlated
to basement membrane thickness and airway hyperre-
sponsiveness in patients with asthma. J. Allergy Clin. Im-
munol. 2002;110:873-878.
22. Kuhn C, Mason R. Immunolocalization of SPARC, tenas-
cin and thrombospondin in pulmonary fibrosis. Am. J.
Physiol. 1998;274:L1049-1057.
23. Chakir J, Laviolette M, Boutet M, Laliberte R, Dube J,
Boulet L. Lower airway remodeling in nonasthmatic sub-
jects wuth allergic rhinitis. Lab. Invest. 1996;75:735-774.
24. Boulet LP, Turcotte H, Laviolette M et al. Airway hyperre-
sponsiveness, inflammation, and subepithelial collagen
deposition in recently diagnosed versus long-standing
mild asthma. Influence of inhaled corticosteroids. Am. J.
Respir. Cri. Care Med. 2000;162:1308-1313.
25. Chu H, Halliday J, Martin R, Leung D, Szefler S, Wenzel
S. Collagen deposition in large airways may not differenti-
ate severe asthma from milder forms of the disease. Am.
J. Respir. Cri. Care Med. 1998;158:1936-1944.
26. Payne D, Rpgers A, Adelroth E et al. Reticular basement
membrane thickness in children with difficult asthma.
Am. J. Respir. Crit. Care Med. 2003;167:78-82.
27. D36 Holgate S, Holloway J, Wilson S, Bucchieri F, Puddi-
coombe S, Davies D. Epithelial-mesenchymal communi-
cation in the pathogenesis of chronic asthma. Proc. Am.
Thorac. Soc. 2004;1:93-98.
28. Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S. Identifi-
cation of circulating fibrocytes as precursors of bronchial
myofibroblasts in asthma. J. Immunol. 2003;171:380-389.
29. Batra V, Musani A, Hastie AT et al. Bronchoalveolar lav-
age fluid concentrations of transforming growth factor
(TGF)-beta1, TGF-beta2, interleukin(IL)-4 and IL-13 after
segmental allergen challenge and their effects on alpha-
smooth muscle actin and collagen III synthesis by pri-
mary human lung fibroblasts. Clin. Exp. Allergy 2004;34:
437-444.
30. Ebina M, Takahashi T, Chiba T et al. Cellular hypertro-
phy and hyperplasia of airway smooth muscles underly-
ing bronchial asthma. A-3-D morphometric study. Am.
Rev. Respir. Dis. 1993;148:720-726.
31. Hirst SJ, Martin JG, Bonacci JV et al. Proliferative aspects
of airway smooth muscle. J. Allergy Clin. Immunol. 2004;
114(Suppl):S2-17.
32. Black JL, Roth M, Lee J et al. Mechanisms of airway Re-
modeling. Am. J. Respir. Crit. Care Med. 2001;164:S63-
S66.
33. Cantley lC. The phosphoinositide 3-kinase pathway. Sci-
ence 2002;296:1655-1657.
34. Krymskaya VP, Penn RB, Orsini MJ et al. Phosphatidyli-
nositol 3-kinase mediates mitogen-induced human airway
smooth muscle cell proliferation. Am. J. Physiol. Lung
Cell. Mol. Physiol. 1999;277:l65-78.
35. Scott PH, Belham CM, Al-Hafidh J et al. A regulatory role
for camp in phosphatidylinositol 3-kinasep70 ribosomal
S6 kinase-mediated DNA synthesis in platelet-derived-
growth-factor-stimulated bovine airway smooth-muscle
cells. Biochem. J. 1996;318:965-971.
36. Simon AR, Takahashi S, Severgnini M, Fanburg BL, Co-
chran BH. Role of the JAK-STAT pathway in PDGF-
stimulated proliferation of human airway smooth muscle
cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002;282:
L1296-1304.
37. Benayoun L, Druilhe A, Dombert MC, Aubier M, Preto-
lan M. Airway structural alterations selectivety associated
with severe asthma. Am. J. Respir. Crit. Care Med. 2003;
167:1360-1368.
38. Wruff PG, Dolganovood GM, Ferrando RE et al. Hyper-
plasia of smooth muscle in mild to moderate asthma with-
out changes in cell size or gene expression. Am. J. Respir.
Crit. Care Med. 2004;169:1001-1006.
39. Mukhina S, Stepanova V, Traktouev D et al. The chemo-
tactic action of urokinase on smooth muscle cells is de-
pendent on its kringle domain. J. Biol. Chem. 2000;275:
16450-16458.
40. Krymskkaya VP, Goncharov DA, Eszterhas A et al. Src is
necessary and sufficient for human airway smooth muscle
cell proliferation and migration. FASEB J. 2005;19:428-
430.
41. Saunders MA, Mitchell JA, Seldon PM et al. Release of
granulocyte-macropharge colony stimulationg factor by
human cultured airway smooth muscle cells: suppression
by dexamethasone. Br. J. Pharmachol. 1997;120:545-546.
42. Hallsworth MP, Soh CPC, Twort CHC, Lee TH, Hirst SJ.
Cultured human airway smooth muscle cells stimulated
by interleukin-1β enhance eosinophil survival. Am. J.
Respir. Cell Mol. Biol. 1998;19:910-919.
43. Akers IA, Parsons M, Hill MR et al. Mast cell tryptase
stimulates human lung fibroblast proliferation via protea-
se-activated receptor-2. Am. J. Physiol. Cell Mol. Physiol.
2000;278:L193-201.
44. Rennard SI, Basset G, Lecossier D et al. Estimation of the
volume of epithelial lining fluid recovered by lavage using
urea as a marker of dilution. J. Appl. Physiol. 1986;88:532-
538.
45. Tam EK, Caughey GH. Degradation of airway neutropep-
tides by human lung tryptase. Am. J. Respir Cell Mol. Biol.
1990;3:27-32.
46. Ammit AJ, Bekir SS, Johnson PRA et al. Mast cell num-
bers are increased in the smooth muscle of human sensi-
tized isolated bronchi. Am. J. Respir. Crit. Care Med. 1997;
155:1123-1129.
47. Brightling CE, Bradding P, Symon FA et al. Mast-cell in-
filatration of airway of airway smooth muscle in asthma.
N. Engl. J. Med. 2002;346:1699-1705.
48. Gruber BL, Kew RP, Jelaska A et al. Human mast cells ac-
tivate fibroblasts. J. Immunol. 1997;158:2310-2317.
49. Cairns JA, Walls AF. Mast cell tryptase is a mitogen for
epithelial cells. Stimulation of IL-8 production and inter-
cellular adhesion molecule-a expression. J. Immunol.
1996;156:275-283.
50. Brightling CE, Bradding P, Symon FA, Holgate ST, Ward-
law AJ, Pavord ID. Mast-cell infiltration of airway smooth
muscle in asthma. N. Engl. J. Med. 2002;346:1699-1705.
51. Berger P, Perng DW, Thabrew H et al. Tryptase and ag-
inists of PAR-2-induce the proliferation of human airway
smooth muscle cells. J. Appl. Physiol. 2001;91:1372-1379.
52. B67 Rajah R, Nunn S, Herrick D, Grunstein MM, Cohen
P. LTD-4 induces matrix metalloproteinase-1 which func-
tion as IGFBP protease in airway smooth muscle cells.
Am. J. Physiol. Lung Cell. Mol. Physiol. 1996;271:L1014-
Tagaya E et al.
340 Allergology International Vol 56, No4, 2007 www.jsaweb.jp
1022.
53. Foda HD, George S, Rollo E et al. Regulation of gela-
tinases in human airway smooth muscle cells: mechanism
of progelatinase A activation. Am. J. Physiol. Lung Cell.
Mol. Physiol. 1999;277:L174-182.
54. Elshaw SR, Henderson N, Knox AJ, Watson SA, Buttle
DJ, Johnson SR. Mateix metalloproteinase expression and
activity in human airway smooth muscle cells. Br. J. Phar-
macol. 2004;142:1318-1324.
55. Yu Q, Stamenkovic I. Cell surface-localized matrix meta-
lloproteinase-9 proteolytically activates TGF-β and pro-
motes tumor invasion and angiogenesis. Genes Dev. 2000;
14:163-176.
56. Van Eerdewegh P, Little RD, Dupuis J et al. Association of
the ADA33 gene with asthma and bronchial hyperrespon-
siveness. Nature 2002;418:426-430.
57. Clauss M. Molecular biology of the VEGF and the VEGF
receptor family. Semin. Thromb. Hemost. 2000;26:561-
569.
58. Hoshino M, Nakamura Y, Hamid QA. Gene expression of
vascular endothelial growth factor and receptors and an-
giogenesis in bronchial asthma. J. Allergy Clin. Immunol.
2001;107:1034-1038.
59. Lee YC, Kwak Y-G, Song CH. Contribution of vascular en-
dothelial growth factor hyperresponsivor to airway hyper-
responsiveness and inflammation in a murine model of
toluene diisocyanate-induced asthma. J. Immunol. 2002;
186:3395-3600.
60. Einarsson O, Geba GP, Zhu Z, Landry M, Elias JA.
Interleukin-11: stimulation invivo and in vitro by respira-
tory virusus and induction of airways hyperresponsive-
ness. J. Clin. Invest. 1996;97:915-924.
61. Schwarze J, Gelfand EW. Respiratory viral infection as
promoters of allergic sensitization and asthma in animal
models. Eur. Repir. J. 2002;19:341-349.
62. Wills-Krap M, Luyimbazi J, Xu X et al. Interleukin-13 cen-
tral mediator of allergic asthma. Science 1998;282:2258-
2260.
63. Zhu Z, Homer RJ, Wang Z et al. Pulmonary expression of
interleukin-13 causes inflammation, mucus hypersecre-
tion, subepithelial fibrosis, physiologic abnormalities and
eotaxin production. J. Clin. Invest. 1999;103:779-788.
64. van der Toorn LM, Overbeek SE, de jongste JC et al. Air-
way inflammation is present during clinical remission of
atopic asthma. Am. J. Respir. Crit. Care Med. 2001;164:
2107-2113.
65. Ingram JL, Rice AB, Geisenhoffer K et al. IL-13 and IL-1
beta promote lung fibroblast growth through coordinated
up-regulation of PDGF-AA and PDGF-Ralpha. FASEB J.
2004;18:1132-1134.
66. McGraw DW, Almoosa KF, Paul RJ, Kobilka BK, Liggett
SB. Antithetic regulation by beta-adrenergic receptors of
Gq receptor signaling via phospholipase C underlies the
airway beta-agonist paradox. J. Clin. Invest. 2003;112:619-
626.
67. Nishimura K, Tamaoki J, Isono K et al. β-adrenergic
receptor-mediated growth of human airway epithelial cell
line. Eur. Respir. J. 2002;20:353-358.
68. Tamaoki J, Tagaya E, Kawatani K et al. Airway mucosal
thickening and bronchial hyperresponsiveness induced
by inhaled β2-agonist in mice. Chest 2004;126:205-212.
69. Fmandes D, Guida E, Koutsuoubos V et al. Glicocorti-
coids inhibit proliferation, cyclin D1 expression, and reti-
noblastoma protein phophorylation,but not activity of the
extracellular-regulated kinases in human cultured airway
smooth muscle. Am. J. Respir. Cell Mol. Biol. 1992;21:77-
88.
70. Roth M, Johnson PR, Borger P et al. Dysfunctional intrac-
tion of CEBP alpha and the glucocorticoid receptor in
asthmatic bronchial smooth-muscle cells. N. Engl. J. Med.
2004;351:560-574.
71. Bergeron C, Hauber HP, Gotfried M et al. Evidence of re-
modeling in peripheral airways of patients with mild to
moderate asthma: Effect of hydrofluoroalkaneflunisolide.
J. Allergy Clin. Immunol. 2005;116:983-989.
72. Panettieri PA Jr, Tan EM, Ciocca V et al. Effects of LTD4
on human airway smooth muscle cell proliferation, matrix
expression, and contraction in vitro: Differential sensitiv-
ity to cysteinyl leukotriene receptor antagonists. Am. J.
Respir. Cell Mol. Biol. 1998;19:453-461.
73. Liu YC, Khawaja AM, Rogers DF. Effects of the cycteinyl
leukotriene receptor antagonists pranlukast and zafirlu-
kast on tracheal mucus secretion in ovalbumin-sensitized
guinea-pigs in vitro. Br. J. Pharmacol. 1998;124:563-571.
